Revenue Performance - For the six months ended June 30, 2025, the company's revenue decreased by approximately RMB 52.9 million or 36.2% due to a challenging market environment [12]. - Revenue for the six months ended June 30, 2025, was RMB 93,156 thousand, a decrease of 36.2% compared to RMB 146,086 thousand for the same period in 2024 [65]. - The company's main revenue source, DHA products, contributed approximately 99.0% of total revenue for the six months ended June 30, 2025, down from 96.2% in the same period of 2024 [13]. - The average selling price of DHA products decreased from approximately RMB 210.3 to RMB 189.8 per unit, reflecting increased competition and consumer downgrade in the Chinese economy [16]. - Major customers contributing over 10% of total revenue included Customer B with RMB 21,450,000 and Customer A with RMB 11,851,000 for the six months ended June 30, 2025 [88]. Profitability and Expenses - Gross profit for the six months ended June 30, 2025, was approximately RMB 62.3 million, a decline of 40.7% compared to the previous period [16]. - The gross profit margin slightly decreased to 66.8% from 71.8% in the same period of 2024, primarily due to pricing pressure from competition [16]. - Profit attributable to owners decreased by 95.3% to approximately RMB 2.1 million for the six months ended June 30, 2025, down from RMB 45.3 million in the same period of 2024 [21]. - The company reported a net profit of RMB 2,129 thousand for the six months ended June 30, 2025, a significant decline from RMB 45,281 thousand in the previous year [65]. - The total tax expense for the six months ended June 30, 2025, was RMB 10,286,000, an increase from RMB 6,418,000 in the same period of 2024 [94]. - The company’s total comprehensive loss for the six months ended June 30, 2025, was RMB 4,400,000, compared to a total comprehensive income of RMB 48,130,000 for the same period in 2024 [69]. Operating Costs - The company's sales cost for the six months ended June 30, 2025, was approximately RMB 30.9 million, a decrease of 24.9% from RMB 41.1 million in the previous period [15]. - Sales and distribution expenses for the six months ended June 30, 2025, were approximately RMB 38.9 million, compared to RMB 48.1 million for the same period in 2024, reflecting a decrease [18]. - Administrative and other operating expenses increased to approximately RMB 14.5 million for the six months ended June 30, 2025, from RMB 12.1 million in the same period of 2024 [19]. - Other income decreased from approximately RMB 12.8 million to RMB 4.2 million, mainly due to a reduction in government subsidies [17]. Cash Flow and Financial Position - The company has a cash and cash equivalents balance of RMB 423,300 thousand as of June 30, 2025, an increase from RMB 235,817 thousand at the end of 2024 [66]. - The net cash generated from operating activities for the six months ended June 30, 2025, was RMB 13,906,000, a decrease of 56.8% compared to RMB 32,193,000 for the same period in 2024 [71]. - The net cash generated from investing activities was RMB 2,217,000, compared to RMB 459,000 in the previous year, indicating a significant increase [71]. - The net cash generated from financing activities was RMB 171,402,000, a substantial increase from a net cash used of RMB 1,758,000 in the prior year [71]. - The group maintained a prudent treasury policy, ensuring a healthy level of liquidity throughout the reporting period [28]. Share Capital and Dividends - The board has resolved not to recommend an interim dividend for the six months ended June 30, 2025 [32]. - The company declared a final dividend of RMB 0.05 per ordinary share for the year 2024, totaling RMB 50,000,000 [97]. - The group had no bank loans as of June 30, 2025, and completed a global offering of 250 million shares at HKD 0.80 per share, which is expected to support future business development [23]. - The net proceeds from the global offering amounted to approximately HKD 124.0 million, with HKD 99.3 million remaining unutilized as of June 30, 2025 [59]. - The company completed a global offering on January 10, 2025, issuing 250,000,000 new ordinary shares at a price of HKD 0.8 per share, raising a total of HKD 200,000,000 (approximately RMB 188,260,000) [108]. Employee and Management Compensation - The group employed 50 staff as of June 30, 2025, with employee costs amounting to approximately RMB 6.4 million for the six months ended June 30, 2025, compared to RMB 6.2 million in the same period of 2024 [30]. - The remuneration for key management personnel, including directors, increased to RMB 3,189,000 for the six months ended June 30, 2025, compared to RMB 1,693,000 for the same period in 2024 [110]. - The company experienced a decrease in discretionary bonuses for management, from RMB 294,000 in 2024 to RMB 48,000 in 2025 [110]. - The contributions to defined contribution plans for management personnel increased from RMB 200,000 in 2024 to RMB 454,000 in 2025 [110]. Governance and Compliance - The company’s directors and senior executives are required to disclose their interests in shares and related securities under the Securities and Futures Ordinance [41]. - The company has not received any notifications from individuals regarding their shareholdings that require disclosure under the Securities and Futures Ordinance as of June 30, 2025 [44]. - The company’s governance structure allows for the board to determine the eligibility of participants in the stock option plan based on various factors [47]. - The company’s directors may seek independent professional advice when necessary, with costs borne by the company [39].

Group 1 - Newman (02530) announced the resignation of its auditor, Fuhua Mazars, effective from September 19, 2025, due to a failure to reach an agreement on the audit fees for the consolidated financial statements for the fiscal year ending December 31, 2025 [1] - The board of directors approved the appointment of Guotai Junan (Hong Kong) CPA Limited as the new auditor to fill the vacancy left by Fuhua Mazars, effective from September 19, 2025, until the conclusion of the next annual general meeting [1]

Core Viewpoint - Newman (02530) announced the resignation of its auditor, Fuhua Mazars, effective September 19, 2025, due to a failure to reach an agreement on the audit fees for the consolidated financial statements for the fiscal year ending December 31, 2025 [1] Group 1 - The resignation of Fuhua Mazars was prompted by disagreements over audit fees [1] - The board approved the appointment of Guotai Junan (Hong Kong) CPA Limited as the new auditor to fill the vacancy left by Fuhua Mazars, effective September 19, 2025 [1] - The new auditor will serve until the conclusion of the next annual general meeting of the company [1]

Core Viewpoint - Newman (02530.HK) announced the resignation of its auditor, Fuhua Mazars, effective September 19, 2025, due to a failure to reach an agreement on the audit fees for the consolidated financial statements for the fiscal year ending December 31, 2025 [1] Group 1 - The board of directors approved the appointment of Guofu Haohua as the new auditor to fill the vacancy left by Fuhua Mazars' resignation, effective September 19, 2025 [1] - The new auditor's term will last until the conclusion of the next annual general meeting of the company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Numans Health Food Holdings Company Limited 紐曼思健康食品控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2530） 董事會宣佈，富睿瑪澤會計師事務所有限公司（「富睿瑪澤」）已辭任本公司核數師， 自二零二五年九月十九日起生效，原因為本公司與富睿瑪澤未能就審核本集團截至 二零二五年十二月三十一日止財政年度的綜合財務報表的審計費用達成共識。 富睿瑪澤已確認，除上文所披露者外，概無其他有關其辭任本公司核數師的事宜須 提請本公司股東（「股東」）垂注。 董事會及董事會審核委員會（「審核委員會」）確認，除上文有關審計費用的披露外， 富睿瑪澤與本公司並無任何意見分歧，且概無有關上述更換核數師的事宜或情況須 提請股東垂注。 董事會進一步宣布，於本公告日期，富睿瑪澤並未就本集團截至二零二五年十二月 三十一日止年度的綜合財務報表開展任何審計工作。因此預期更換核數師不會對 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 紐曼思健康食品控股有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02530 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.001 HKD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.001 HKD | | 5,000,000 | 本月底法定 ...

Core Viewpoint - The Hong Kong IPO market is active, with 57 new listings and a total fundraising amount of 131.9 billion HKD as of August 25. However, many companies face challenges in meeting both domestic and Hong Kong regulatory requirements for listing [1]. Group 1: Hong Kong IPO Overview - As of August 25, 2023, there have been 57 new IPOs on the Hong Kong Stock Exchange, raising a total of 131.9 billion HKD [1]. - There are currently 211 companies that have submitted applications for listing in Hong Kong [1]. Group 2: Listing Challenges - Companies looking to list in Hong Kong must comply with both domestic laws and Hong Kong's regulatory framework, making the IPO preparation process complex and demanding [1]. Group 3: Resources for Companies - A compilation of Hong Kong listing rules and disclosure documents for domestic companies planning to list in Hong Kong has been organized to assist businesses in understanding the latest regulatory dynamics [1].

Group 1 - The company Newman (02530) reported a mid-term performance for 2025, with revenue of 93.156 million yuan, representing a year-on-year decrease of 36.23% [1] - The net profit for the period was 2.129 million yuan, showing a significant year-on-year decline of 95.3% [1] - The basic earnings per share were 0.22 cents [1]

Core Viewpoint - Newman (02530) reported a significant decline in its mid-year performance for 2025, with a notable drop in both revenue and profit margins [1] Financial Performance - The company reported revenue of 93.156 million yuan, representing a year-on-year decrease of 36.23% [1] - Net profit for the period was 2.129 million yuan, which reflects a substantial year-on-year decline of 95.3% [1] - Basic earnings per share were recorded at 0.22 cents [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Numans Health Food Holdings Company Limited 紐曼思健康食品控股有限公司 截至二零二五年六月三十日止六個月的 中期業績公告 | 財務摘要 | | | | --- | --- | --- | | | 截至六月三十日止六個月 | | | | 二零二五年 | 二零二四年 | | | 人民幣千元 | 人民幣千元 | | | （未經審核） | （經審核） | | 收益 | 93,156 | 146,086 | | 銷售成本 | 30,893 | 41,123 | | 毛利 | 62,263 | 104,963 | | 除稅前溢利 | 12,415 | 51,699 | | 期內溢利 | 2,129 | 45,281 | – 1 – 紐曼思健康食品控股有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及 其附屬公司（統稱「本集團」）截至二零二五年六月三十日 ...